Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 20Recruiting 8Not yet recruiting 6Active not recruiting 4Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms by Site 1Mouth Neoplasms 1Lung Neoplasms 1Lung Diseases 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Neoplasms 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Completed
21 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Nanfang Hospital, Southern Medical University

Phase 2 Completed
39 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡